Objective To investigate the association between nirmatrelvir plus ritonavir (NMV-r) and the
outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19) …

Objectives This study investigated the outcomes of underweight patients with COVID-19 and
the effectiveness of antiviral agents in this population. Methods A retrospective cohort study …

Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …

Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …

The aim of this study was to investigate the clinical efficacy of a combination of nirmatrelvir
and ritonavir (NMV‐r) for treating COVID‐19 in patients with diabetes mellitus (DM). This …

Background This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV-r) in
treating patients with COVID-19 who have preexisting cardiovascular diseases (CVDs) …

Background: A randomized controlled trial involving a high-risk, unvaccinated population
that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir …

Objective To estimate the effectiveness of nirmatrelvir, compared with no treatment, in
reducing admission to hospital or death at 30 days in people infected with the SARS-CoV-2 …

The effect of nirmatrelvir plus ritonavir (NMV‐r) on post‐acute COVID‐19 sequelae beyond 3
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …

This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV‐r) in treating
patients with coronavirus disease‐2019 (COVID‐19) and substance use disorders (SUDs) …